A7856
Acipimox
≥99% (TLC)
Synonym(s):
2-Carboxy-5-methylpyrazine 4-oxide, 5-Methylpyrazinecarboxylic acid 4-oxide
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C6H6N2O3
CAS Number:
Molecular Weight:
154.12
EC Number:
UNSPSC Code:
12352205
NACRES:
NA.79
Recommended Products
Assay
≥99% (TLC)
form
powder
color
off-white to faint yellow
mp
177-180 °C
storage temp.
2-8°C
InChI
1S/C6H6N2O3/c1-4-2-7-3-5(6(9)10)8(4)11/h2-3H,1H3,(H,9,10)
InChI key
DNRXJHATQULEHC-UHFFFAOYSA-N
Related Categories
Biochem/physiol Actions
Acipimox, also known as olbemox, is a nicotinic acid analog. It functions as an anti-lipolytic drug and vasodilator. Acipimox may be used in various metabolic studies involving insulin and ghrelin. It lowers total cholesterol and total triglycerides, which helps in the treatment of hyperlipidemia.
Niacin-derived, vasodilator studied for its lipid-lowering effect.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Mads Halbirk et al.
American journal of physiology. Heart and circulatory physiology, 299(4), H1220-H1225 (2010-08-17)
Circulating free fatty acids (FFAs) may worsen heart failure (HF) due to myocardial lipotoxicity and impaired energy generation. We studied cardiac and whole body effects of 28 days of suppression of circulating FFAs with acipimox in patients with chronic HF.
Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression
Cordido F, et al.
The Journal of clinical endocrinology and metabolism, 81(3), 914-918 (1996)
Fabrizio Montecucco et al.
American journal of physiology. Endocrinology and metabolism, 300(4), E681-E690 (2011-01-27)
Metabolic syndrome is a proatherosclerotic condition clustering cardiovascular risk factors, including glucose and lipid profile alterations. The pathophysiological mechanisms favoring atherosclerotic inflammation in the metabolic syndrome remain elusive. Here, we investigated the potential role of the antilipolytic drug acipimox on
Hanna-Riikka Lehto et al.
The Journal of clinical endocrinology and metabolism, 97(9), 3277-3284 (2012-07-05)
We tested the hypothesis that a persistent reduction in free fatty acid (FFA) levels improves cardiac function and systemic insulin sensitivity via a reduction in the myocardial and skeletal muscle adiposities and a modulation in adipokine release. Study subjects (body
J Huang et al.
Drug research, 63(2), 79-83 (2013-03-01)
The study was designed to compare the pharmacokinetic parameters and relative bioavailability of a newly generic acipimox 250-mg tablets (test formulation) with a branded 250-mg tablets (reference formulation). A single-dose, randomized-sequence, 2-way crossover study was conducted in 20 healthy Chinese
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service